Therapy-related myelodysplastic syndrome

Bibliography

• SDNimer. Myelodysplastic syndromes. Blood 2008;111:4841-51
   PubMed Web of Science ®Google Scholar
• JWVardiman, JThiele, DAArber, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51
   PubMed Web of Science ®Google Scholar
• AJosting, SWiedenmann, JFranklin, et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003;21:3440-6
   PubMed Web of Science ®Google Scholar
• KWheatley, CLBrookes, AJHowman, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML 11 and LRFAML14 trials. Br J Hematol 2009;145:598-605
   PubMed Web of Science ®Google Scholar
• LBTravis, RECurtis, BGlimelius, et al. Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst 1993;85:1932-7
   PubMed Web of Science ®Google Scholar
• JPederson-Bjergaard, MKAndersen, MTAndersen, et al. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008;22:240-8
   PubMed Web of Science ®Google Scholar
• CHPui, RCRibiero, MLHancock, et al. Acute myeloid leukemia in children treated with epidophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7
   PubMed Web of Science ®Google Scholar
• JPNeglia, ATMeadows, LLRobison, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330-6
   PubMed Web of Science ®Google Scholar
• SBhatia, MDKrailo, ZChen, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the Children’s Oncology Group. Blood 2007;109:46-51
   PubMed Web of Science ®Google Scholar
• YChen, ZEstrov, SPierce, et al. Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor. Leuk Lymphoma 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• HHuh, SHyung-Lee, HKYoo, et al. Therapy-related myeloid neoplasms in 39 korean patients: a single institution experience. Ann Lab Med 2013;33:97-104
   PubMed Web of Science ®Google Scholar
• JWVardiman, NLHarris, RDBrunning. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302
   PubMed Web of Science ®Google Scholar
• JPedersen-Bjergaard, MKAndersen, DHChristiansen, et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909-12
   PubMed Web of Science ®Google Scholar
• JPedersen-Bjergaard, PPhilip. Balanced translocation involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991;78:1147-8
   PubMed Web of Science ®Google Scholar
• MWestman, JPedersen-Bjergaard, MTAndersen, MKAndersen. IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7) (q10;p10). Leukemia 2013;27:957-9
   PubMed Web of Science ®Google Scholar
• OAbel-Wahab, RLLevine. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 2013;121:3563-72
   PubMed Web of Science ®Google Scholar
• AKrishnan, SBhatia, MLSlovak, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588-93
   PubMed Web of Science ®Google Scholar
• EWMilligan, MCRuiz de Elviar, HJKolb, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT, EBMT Lymphoma and Late Effects Working Parties European Group for Blood and Marrow Transplantation. Br J Haematol 1999;106:1020-6
   PubMed Web of Science ®Google Scholar
• SBhatia, NKRamsay, MSteinbuch, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-9
   PubMed Web of Science ®Google Scholar
• JWFriedberg, DNeuberg, RStone, et al. Outcome of patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkins’s lymphoma. J Clin Oncol 1999;17:128-35
   Web of Science ®Google Scholar
• MZKoontz, SJHorning, RBalise, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013;31:592-8
   PubMed Web of Science ®Google Scholar
• SBhatia, LLRobison, OOberlin, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996;334:745-51
   PubMed Web of Science ®Google Scholar
• SBhatia, HNSather, OBPabustan, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002;99:4257-64
   PubMed Web of Science ®Google Scholar
• LBTravis, EJHolowaty, KBergfeldt, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999;340:351-7
   PubMed Web of Science ®Google Scholar
• LBTravis, MAndersson, MGospodarowicz, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165-71
   PubMed Web of Science ®Google Scholar
• RGovindarajan, SJagannath, JTFlick, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Hematol 1996;95:349-53
   PubMed Web of Science ®Google Scholar
• JPedersen-Bjergaard, MPedersen, JMyhre, et al. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to BEAM transplantation procedure. Leukemia 1997;11:1654-60
   PubMed Web of Science ®Google Scholar
• CWheeler, AKhurshid, JIbrahim, et al. Incidence of post-transplant myelodysplasia/acute leukemia in non-Hodgkin’s lymphoma patients compared with Hodgkin’s disease patients undergoing autologous transplantation following cyclophosphamide, carmustine and etoposide (CBV). Leuk Lymphoma 2001;40:499-509
   PubMed Web of Science ®Google Scholar
• WMCovert, JRMurillo, JECox. Incidence of myelodysplastic syndromes in patients receiving concurrent myelosuppressive chemotherapy and pegfilgrastim. J Oncol Pharm Pract 2001;17:366-71
   Google Scholar
• GLenz, MDreyling, ESchiegnitz, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926-33
   PubMed Web of Science ®Google Scholar
• PCremin, MFlattery, SRMcCann, et al. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996;7:745-6
   PubMed Web of Science ®Google Scholar
• MIshikawa, KNakayama, MTRahman, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report. Eur J Gynaecol Oncol 2014;35:443-8
   PubMed Web of Science ®Google Scholar
• DJLohmann, HHasle. Hematological changes mimicking Myelodysplastic Syndrome following treatment of osteosarcoma. J Pediatr Hematol Oncol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• LSMorton, GCDores, MTucker, et al. Evolving risk of therapy-related acute myeloid leukemia following chemotherapy among adults in the United States, 1975-2008. Blood 2013;121:2996-3004
   PubMed Web of Science ®Google Scholar
• DAEichenauer, EThielen, HHaverkamp, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome in patients with Hodgkin lymphoma. Blood 2014;123:1658-64
   PubMed Web of Science ®Google Scholar
• SBathia. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol 2013;40:666-75
   PubMed Web of Science ®Google Scholar
• CAFelix, AHWalker, BJLange, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-81
   PubMed Web of Science ®Google Scholar
• JDHayes, JUFlanagan, IRJowsey. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88
   PubMed Web of Science ®Google Scholar
• JMAllan, CPWild, SRollinson, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001;98:11592-7
   PubMed Web of Science ®Google Scholar
• PBolufer, MCollado, EBarragan, et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 2007;136:590-6
   PubMed Web of Science ®Google Scholar
• ICasorelli, JOffman, IMele, et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2003;2:547-9
   PubMed Web of Science ®Google Scholar
• RBhatia, KVan Heizjen, AKomiya, et al. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol 2005;23:6699-711
   PubMed Web of Science ®Google Scholar
• WWAu, SASalama, CHSierra-Torres. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003;111:1843-50
   PubMed Web of Science ®Google Scholar
• CSeedhouse, RFaulkner, NAshraf, et al. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004;10:2675-80
   PubMed Web of Science ®Google Scholar
• CSeedhouse, RBainton, MLewis, et al. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002;100:3761-6
   PubMed Web of Science ®Google Scholar
• JDubois, GEtienne, ALaroche-Clary, et al. Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms. Eur J Cancer 2014;50:418-24
   PubMed Web of Science ®Google Scholar
• EFabiani, LFianchi, GFalconi, et al. The BCL2L10Leu21ARg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes. Leuk Lymphoma 2014;55:1538-43
   PubMed Web of Science ®Google Scholar
• HMauritzon, MAlbin, LRylander, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366-78
   PubMed Web of Science ®Google Scholar
• SSmith, MLe Beau, DHuo, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52
   PubMed Web of Science ®Google Scholar
• MJThirman, RALarson. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996;10:293-320
   PubMed Web of Science ®Google Scholar
• FLai, LAGodley, JJoslin, et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 2001;71:235-45
   PubMed Web of Science ®Google Scholar
• HSill, WOlipitz, AZebisch, et al. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol 2011;162:792-805
   PubMed Web of Science ®Google Scholar
• AHCorbert, NOsheroff. When good enzymes go to bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem Res Toxicol 1993;6:585-97
   PubMed Web of Science ®Google Scholar
• CFelix, BLange, MHosler, et al. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage site. Cancer Res 1995;55:4287-92
   PubMed Web of Science ®Google Scholar
• YHarada, HHarada. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations. J Cell Biochem 2011;112:425-32
   PubMed Web of Science ®Google Scholar
• JJWestendorf, CMYamamoto, HLenny, et al. The t(8;21) fusion product, AML-1-ETO associates with C/EBP-alpha, inhibits c(EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 1998;18:322-33
   PubMed Web of Science ®Google Scholar
• LHCastilla, CWijmenga, QWang, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 1996;87:687-96
   PubMed Web of Science ®Google Scholar
• MTVoso, EFabiani, LFianchi, et al. Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2013;27:982-5
   PubMed Web of Science ®Google Scholar
• YJiang, ADunbar, LPGondek, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113:1315-25
   Google Scholar
• SJZhang, RRampal, TManshouri, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012;119:4480-5
   PubMed Web of Science ®Google Scholar
• DBen-Yehuda, SKrichevsky, OCaspi, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996;88:4296-303
   PubMed Web of Science ®Google Scholar
• LZhang, SAWang. A focused review of hematopoietic neoplasms occurring in the therapy-related setting. Int J Clin Exp Pathol 2014;7:3512-23
   PubMed Web of Science ®Google Scholar
• JMalcikova, KStano-Kozubik, BTichy, et al. Detailed analysis of therapy-driven clonal evolution of TP-53 mutations in chronic lymphocytic leukemia. Leukemia 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• SChakravorty, CSun, LFrancisco, et al. Accelerated telomere shorting precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologus transplantation for lymphoma. J Clin Oncol 2009;27:791-8
   PubMed Web of Science ®Google Scholar
• MByrne, RLBennett, XCheng, et al. Progressive genomic instability in the Nup98-HoxD13 model of MDS correlates with loss of the PIG-A gene product. Neoplasia 2014;16:627-33
   PubMed Web of Science ®Google Scholar
• HGreim, DAKaden, RALarson, et al. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci 2014;1310:7-31
   PubMed Web of Science ®Google Scholar
• PGreenberg, CCox, MMLeBeau, et al. International Scoring System for evaluating prognosis in myelodysplastic syndrome. Blood 1997;89:2079-85
   PubMed Web of Science ®Google Scholar
• LMalovati, UGerming, AKuendgen, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndrome. J Clin Oncol 2007;25:3503-10
   PubMed Web of Science ®Google Scholar
• PLGreenberg, HTuechler, JSchanz, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65
   PubMed Web of Science ®Google Scholar
• CYOk, RPHasserjian, PSFox, et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014;28:185-9
   PubMed Web of Science ®Google Scholar
• AQuintas-Cardama, NDaver, HKim, et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014;14:401-10
   PubMed Web of Science ®Google Scholar
• MOrnstein, SMukherjee, SMohan, et al. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. Am J Hematol 2013;89:168-73
   PubMed Web of Science ®Google Scholar
• RALarson, MWernli, MMLe Beau, et al. Short remission durations in therapy-related leukemia despite cytogenetic complete response to high-dose cytarabine. Blood 1988;72:1333-9
   PubMed Web of Science ®Google Scholar
• HMKantarjian, EHEstey, MJKeating. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 1993;7:81-107
   PubMed Web of Science ®Google Scholar
• KTakeyama, MSeto, NUlke, et al. Therapy related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000;71:144-52
   PubMed Web of Science ®Google Scholar
• LAGodley, UPNjiaju, MGreen, et al. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma 2010;51:995-1006
   PubMed Web of Science ®Google Scholar
• SKayser, MZucknick, KDöhner, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012;119:551-8
   PubMed Web of Science ®Google Scholar
• VHDuong, JELancet, EAlrawi, et al. Outcome of azacytidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res 2013;37:510-15
   PubMed Web of Science ®Google Scholar
• LFianchi, MCriscuolo, MLunghi, et al. Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol 2012;5:44
   PubMed Web of Science ®Google Scholar
• CBally, SThepot, BQuesnel, et al. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leuk Res 2013;37:637-40
   PubMed Web of Science ®Google Scholar
• IYakoub-Agha, Pde La Salmoniere, PRibaud, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000;18:963-71
   PubMed Web of Science ®Google Scholar
• RPWhiterspoon, HJDeeg, BStorer, et al. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol 2001;19:2134-41
   PubMed Web of Science ®Google Scholar
• CChang, BEStorer, BLScott, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007;210:1379-87
   Google Scholar
• MLitzow, STarima, WPerez, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010;115:1850-7
   PubMed Web of Science ®Google Scholar
• NKröger, RBrand, Avan Biezen, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009;94:542-9
   PubMedGoogle Scholar
• NKröger, RBrand, Avan Biezen, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006;37:183-9
   PubMed Web of Science ®Google Scholar
• RSiegel, CDeSantis, KVirgo, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41
   PubMed Web of Science ®Google Scholar
• MRCorces-Zimmerman, RMajeti. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia 2014;28:2276-82
   PubMed Web of Science ®Google Scholar
• EBulycheva, MRauner, HMedyouf, et al. Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• FHirata, THarada, GBCorcoran, AHirata. Dietary flavonoids bind to mono-ubiquitinated annexin A1 in nuclei, and inhibit chemical induced mutagenesis. Mutat Res Fundam Mol Mech Mutagen 2014;759:29-36
   PubMed Web of Science ®Google Scholar
• REdenharder, RRauscher, KLPlatt. The inhibition by flavonoids of 2-amino-3-methylimidazo[4,5-f]quinoline metabolic activation to a mutagen: a structure-activity relationship study. Mutat Res 1997;379:21-32
   PubMed Web of Science ®Google Scholar
• PWSnijman, SSwanevelder, EJoubert, et al. The antimutagenic activity of the major flavonoids of rooibos (Aspalathus linearis): some dose-response effects on mutagen activation-flavonoid interactions. Mutat Res 2007;631:111-23
   PubMed Web of Science ®Google Scholar
• FSquadrito, HMarini, ABitto, et al. Genistein in the metabolic syndrome: results of a randomized clinical trial. J Clin Endocrinol Metab 2013;98:3366-74
   PubMed Web of Science ®Google Scholar